Natera
<UNKNOWN> · 1 known investors
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions. The company serves patients, physicians, and healthcare systems across oncology, women's health, and organ health.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
<
<UNKNOWN>
MR
Matthew RabinowitzCo-founder & Executive Chairman
Investors · 1
In the news
- Natera co-founder Sheena Jonathan sells $410,825 in NTRA stock By Investing.cominvesting.com · 2026
- Natera director Rowan Chapman sells $37,100 in company stock By Investing.cominvesting.com · 2026
- Future Fund LLC Raises Stock Holdings in Natera, Inc. $NTRA - Ticker Reporttickerreport.com · 2026
- Natera (NTRA) Lands New Trial Partnerships, Is The Upside Already Priced In? - Simply Wall St Newssimplywall.st · 2026
- Natera stock hits all-time high at $279.63 By Investing.comca.investing.com · 2026
- Natera stock jumps as investors focus on fresh clinical data and strong growth outlook | Quiver Quantitativequiverquant.com · 2026